GKV Capital Management Co. Inc. Takes $39,000 Position in IQVIA Holdings Inc. (NYSE:IQV)

GKV Capital Management Co. Inc. purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 200 shares of the medical research company’s stock, valued at approximately $39,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Synergy Asset Management LLC acquired a new position in shares of IQVIA in the fourth quarter valued at $33,000. Lee Danner & Bass Inc. bought a new stake in shares of IQVIA during the fourth quarter worth approximately $44,000. Zions Bancorporation N.A. increased its stake in shares of IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock worth $47,000 after purchasing an additional 85 shares during the period. Versant Capital Management Inc grew its holdings in IQVIA by 46.0% in the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock valued at $58,000 after buying an additional 93 shares in the last quarter. Finally, SBI Securities Co. Ltd. bought a new stake in shares of IQVIA in the fourth quarter valued at about $60,000. 89.62% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of analyst reports. Robert W. Baird decreased their target price on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 21st. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th. Stephens initiated coverage on shares of IQVIA in a research report on Friday, December 20th. They set an “overweight” rating and a $250.00 price objective for the company. UBS Group cut their price target on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a report on Friday, February 7th. Finally, Barclays reaffirmed an “equal weight” rating and issued a $170.00 target price (down previously from $235.00) on shares of IQVIA in a report on Thursday, April 10th. Six investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $241.50.

IQVIA Stock Performance

Shares of IQV stock opened at $143.66 on Friday. The stock has a market capitalization of $25.33 billion, a PE ratio of 19.15, a PEG ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a one year low of $135.97 and a one year high of $252.88. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The business’s 50 day simple moving average is $177.57 and its 200 day simple moving average is $197.47.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.